Abstract:Schistosomiasis is one of the most devastating human diseases worldwide. The disease is caused by six species of Schistosoma blood fluke; five of which cause intestinal granulomatous inflammation and bleeding. The current diagnostic method is inaccurate and delayed, hence, biomarker identification using metabolomics has been applied. However, previous studies only investigated infection caused by one Schistosoma spp., leaving a gap in the use of biomarkers for other species. No study focused on understanding the progression of intestinal disease. Therefore, we aimed to identify early gut biomarkers of infection with three Schistosoma spp. and progression of intestinal pathology. We infected 3 groups of mice, 3 mice each, with Schistosoma mansoni , Schistosoma japonicum or Schistosoma mekongi and collected their feces before and 1, 2, 4 and 8 weeks after infection. Metabolites in feces were extracted and identified using mass spectrometer-based metabolomics. Metabolites were annotated and analyzed with XCMS bioinformatics tool and Metaboanalyst platform. From >36,000 features in all conditions, multivariate analysis found a distinct pattern at each time point for all species. Pathway analysis reported alteration of several lipid metabolism pathways as infection progressed. Disturbance of the glycosaminoglycan degradation pathway was found with the presence of parasite eggs, indicating involvement of this pathway in disease progression. Biomarkers were discovered using a combination of variable importance for projection score cut-off and receiver operating characteristic curve analysis. Five molecules met our criteria and were present in all three species: 25-hydroxyvitamin D2, 1α-hydroxy-2β-(3-hydroxypropoxy) vitamin D3, Ganoderic acid Md, unidentified feature with m/z 455.3483, and unidentified feature with m/z 456.3516. These molecules were proposed as trans-genus biomarkers of early schistosomiasis. Our findings provide evidence for disease progression in intestinal schistosomiasis and potential biomarkers, which could be beneficial for early detection of this disease. Schistosomiasis is a parasitic disease caused by the blood fluke Schistosoma . Five species of Schistosoma cause intestinal damage and inflammation, but the current method of diagnosis is not satisfactory because it lacks sensitivity and timeliness. Therefore, we applied metabolomics to identify the overall types and abundance of compounds in biological samples to discover new markers. Previous metabolomic studies focused only on infection with one species, making it difficult to detect disease caused by other species. Moreover, no study examined progression of intestinal disease. In this study, we used a mouse model and metabolomics to investigate changes in the gut environment from the early stage of the disease and identify markers of early infection caused by three different species of Schistosoma . We found that changes in compounds related to lipid metabolism since early infection and some pathways, such as glycosaminoglycan degradation, might be related to intestinal disease. We identified five compounds as early biomarkers of schistosomiasis, which were shared among the three species. These compounds could be used for future biomarker development, which could facilitate diagnosis of schistosomiasis.

Host Urinary Proteins Changed Significantly in Mice Infected with Malaria

The Identification of Urinary Biomarkers for Malaria in Mouse Model

Exploring urinary proteomics and peptidomics biomarkers for the diagnosis of mekong schistosomiasis

Functional Human IgA Targets a Conserved Site on Malaria Sporozoites

Urine proteomics for profiling of mouse toxoplasmosis using liquid chromatography tandem mass spectrometry analysis

Detection of Host Pathways Universally Inhibited after Plasmodium Yoelii Infection for Immune Intervention

[Changes of Urinary Proteins in a Bacterial Meningitis Rat Model].

Absence of apolipoprotein E protects mice from cerebral malaria

Extracellular Proteomic Profiling from the Erythrocytes Infected with Plasmodium Falciparum 3D7 Holds Promise for the Detection of Biomarkers

Identification of trans-genus biomarkers for early diagnosis of intestinal schistosomiasis and progression of gut pathology in a mouse model using metabolomics

Clinicopathological study of potential biomarkers of Plasmodium falciparum malaria severity and complications

Untargeted serum metabolomic profiling for early detection of Schistosoma mekongi infection in mouse model

Genome-wide liver transcriptomic profiling of a malaria mouse model reveals disturbed immune and metabolic responses

Deficiency of migration inhibitory factor influences the gut microbiota of C57BL/6 mice infected with Plasmodium berghei ANKA

Host Serum Mir-223 is a Potential New Biomarker for Schistosoma Japonicum Infection and the Response to Chemotherapy

Host Blood Gene Signatures Can Detect the Progression to Severe and Cerebral Malaria

Increased Neutrophil Percentage and Neutrophil–T Cell Ratio Precedes Clinical Onset of Experimental Cerebral Malaria

Identification of Potential Whole Blood MicroRNA Biomarkers for the Blood Stage of Adult Imported Falciparum Malaria Through Integrated Mrna and Mirna Expression Profiling.

Novel Experimental Mouse Model to Study Malaria-Associated Acute Kidney Injury

Metabolic Changes Reveal the Development of Schistosomiasis in Mice

Disordered Metabolic Profiling in Plasma and Tissues of Mice Infected with Artemisinin-Sensitive and -Resistant Plasmodium Berghei K173 Determined by 1H NMR Spectroscopy